Company / Capital Expenditures
Metagenomi Therapeutics, Inc. Capital Expenditures History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$574.0K
FY2025
5-year range
$574.0K / $9.8M
FY2024-FY2025
Trend
-94.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$574,000 in FY2025.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, capital expenditures decreased 94.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.90 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $574.0K | -94.2% |
| FY2024 | $9.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026